# Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease

> **NCT07118696** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Hamilton Health Sciences Corporation** · enrollment: 1000 (estimated)

## Conditions studied

- Pulmonary TB

## Interventions

- **DRUG:** Extra 600mg of Rifampicin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07118696
- **Lead sponsor:** Hamilton Health Sciences Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2029-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-08-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07118696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07118696, "Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07118696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*